SecBot SecBot
6-K ·Filed May 11, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 6/10
Horizondays Processed6mo ago SEC0001213900-26-054165
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor the conference call at 8:30am ET for additional detail and FDA feedback. Stock could react positively given compelling efficacy in a high-need indication, but early-stage data (n=3) warrants caution. Track enrollment updates and any FDA IDE expansion announcements.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · May 11, 2026 · via day close
Latest settled
+230.39%
T+60 · $3.37
Vs SPY
+226.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $1.02entry
  2. T+1 · 6mo ago 0.00%α +0.14% · $1.02
  3. T+5 · 6mo ago 0.00%α +0.09% · $1.02
  4. T+20 · 5mo ago 0.00%α +0.30% · $1.02
  5. T+60 · 3mo ago +230.39%α +226.00% · $3.37

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced interim results from its U.S. Alpha DaRT recurrent glioblastoma trial (REGAIN) showing 100% local disease control and 67% complete response rate in the first three patients, with one resolved grade 3 SAE. The data is early but highly promising for a deadly cancer with limited treatment options, potentially de-risking the ongoing trial and expanding Alpha Tau's pipeline.

Key Facts

  • 100% local disease control in first three recurrent GBM patients treated with Alpha DaRT
  • 67% complete response rate: two patients had total disappearance of enhancing tumor lesions
  • One grade 3 SAE (seizure with temporary paralysis) resolved with steroids; no unanticipated SAEs
  • FDA requested interim safety analysis before expanding IDE; results support trial continuation
  • Trial enrollment expected up to 10 U.S. patients; primary endpoint is feasibility and safety

Financial Impact

No financial figures disclosed; pre-revenue stage. Positive clinical data may increase probability of regulatory success and partnership value.

clinical trial progressregulatory pathwayfuture revenue potential

Risk Factors

  • Very small sample size (n=3) limits statistical reliability
  • Alpha DaRT not yet approved for any indication; regulatory path uncertain
  • Company has limited cash runway per prior 20-F; potential dilution risk
  • Historical stock performance on positive news has been weak (previous high-score reports led to declines)

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-054165
Document: ea0290048-6k_alpha.htm0001213900-26-054165
Document: 0001213900-26-054165-index-headers.html0001213900-26-054165
Document: 0001213900-26-054165-index.html0001213900-26-054165
Document: 0001213900-26-054165.txt0001213900-26-054165

Track record

14 reports on DRTSW

Performance horizon

8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Viewing Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026